Meriones libycus is the main reservoir of zoonotic cutaneous leishmaniasis in south Islamic Republic of Iran
AbstractA study was made in rural regions around Neiriz city, Fars province in the south of the Islamic Republic of Iran during 2002-03 to further investigate a new focus of zoonotic cutaneous leishmaniasis. Meriones libycus was the dominant rodent [100% of 65 rodents collected] and 4.6% were naturally infected with the amastigote form of Leishmania spp. Promasigotes were identified as L. major. This confirms M. libycus as the main reservoir host of zoonotic cutaneous leishmaniasis in southern parts of the country
Rassi, Y., Javadian, E., Amin, M., Rafizadeh, S., Vatandoost, H. et al. (2006). Meriones libycus is the main reservoir of zoonotic cutaneous leishmaniasis in south Islamic Republic of Iran. EMHJ - Eastern Mediterranean Health Journal, 12 (3-4), 474-477, 2006 http://www.who.int/iris/handle/10665/117109
JournalEMHJ - Eastern Mediterranean Health Journal, 12 (3-4), 474-477, 2006
MetadataShow full item record
Showing items related by title and MeSH subject.
Control of cutaneous leishmaniasis in Afghanistan: achievements and challenges – Lutte contre la leishmaniose cutanée en Afghanistan: progrès accomplis et défis à relever World Health Organization = Organisation mondiale de la Santé (2018-04-27)
Cutaneous leishmaniasis: control in selected countries of the WHO Eastern Mediterranean and African Regions: report of an interregional network meeting, Casablanca, Morocco, 23–24 June 2014 World Health Organization (WHO/HTM/NTD/IDM/2015.4, 2015)
Effectiveness of meglumine antimoniate against L.tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran Karamian, M.; Faroghi Bojd, M.S.; Salehabadi, A.; Hemmati, M.; Barati, D.A. (2015)With limited options to treat cutaneous leishmaniasis, constant monitoring of the rate of resistance to pentavalent antimony-based drugs is needed. This study identified the infecting Leishmania species and evaluated the results of meglumine antimoniate (Glucantime®) therapy in a new focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. Smears from 150 patients showed that 141 patients were infected by L. tropica and 9 by L. major. In total, 141 patients with L. tropica infection completed Glucantime® treatment and ...